Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research

Wu, Xianbo; Yang, Xinwei; Liang, Qi; Xue, Xiali; Huang, Jianli; Wang, Jie; Xu, Yunyun; Tong, Rongsheng; Liu, Maoyu; Zhou, Qin; Shi, Jianyou

doi:10.1016/j.ejmech.2021.113842

Cited by 15 publications

(4 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment resistance is common in the management of glaucoma, with a significant number of patients demonstrating inadequate responses to standard therapeutic interventions such as topical medications, laser trabeculoplasty, or trabeculectomy [103]. The involvement of miRNAs in the mechanisms underlying treatment resistance stems from their ability to modulate the expression of drug transporters, receptors, metabolizing enzymes, and signaling pathways [3].…”

Section: Personalized Medicinementioning

confidence: 99%

miRNA Studies in Glaucoma: A Comprehensive Review of Current Knowledge and Future Perspectives

Dobrzycka,

Sulewska,

Biecek

et al. 2023

IJMS

View full text Add to dashboard Cite

Glaucoma, a neurodegenerative disorder that leads to irreversible blindness, remains a challenge because of its complex nature. MicroRNAs (miRNAs) are crucial regulators of gene expression and are associated with glaucoma and other diseases. We aimed to review and discuss the advantages and disadvantages of miRNA-focused molecular studies in glaucoma through discussing their potential as biomarkers for early detection and diagnosis; offering insights into molecular pathways and mechanisms; and discussing their potential utility with respect to personalized medicine, their therapeutic potential, and non-invasive monitoring. Limitations, such as variability, small sample sizes, sample specificity, and limited accessibility to ocular tissues, are also addressed, underscoring the need for robust protocols and collaboration. Reproducibility and validation are crucial to establish the credibility of miRNA research findings, and the integration of bioinformatics tools for miRNA database creation is a valuable component of a comprehensive approach to investigate miRNA aberrations in patients with glaucoma. Overall, miRNA research in glaucoma has provided significant insights into the molecular mechanisms of the disease, offering potential biomarkers, diagnostic tools, and therapeutic targets. However, addressing challenges such as variability and limited tissue accessibility is essential, and further investigations and validation will contribute to a deeper understanding of the functional significance of miRNAs in glaucoma.

show abstract

Section: Personalized Medicinementioning

confidence: 99%

miRNA Studies in Glaucoma: A Comprehensive Review of Current Knowledge and Future Perspectives

Dobrzycka,

Sulewska,

Biecek

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Prostaglandin analogues (PGAs) are usually the first choice as they have the highest potency, once-daily administration and a good safety profile [14]. There is increasing availability of preservative-free formulas worldwide.…”

Section: Medical Therapymentioning

confidence: 99%

When to treat ocular hypertension?

Franco Díez Cattini

2023

Ocular Hypertension - New Advances

View full text Add to dashboard Cite

How to decide which patient should receive treatment to prevent conversion to glaucoma? Ocular hypertension is the only treatable risk factor for glaucoma, yet not all patients with hypertension develop glaucoma, and not all glaucoma patients have ocular hypertension. Deciding when and how to start treatment can be challenging, particularly in patients without other risk factors. When facing this dilemma one should ponder: the patient’s risk tolerance/avoidance, the prospect of long-term topical treatment including adverse effects, the psychological and economical burden of a pre-disease state and its treatment, treatment compliance, and the possibility of over-treating. New tools such as AI-guided image analysis, improved testing algorithms, and novel minimally invasive treatments may help control and weigh this risk factor more conveniently, avoiding over-treatment but preventing glaucoma-related blindness.

show abstract

“…Typically, medication is the preferred treatment choice for patients with glaucoma [ 18 ]. In recent decades, several small-molecule agents, such as cholinergic agents [ 19 , 20 ], beta-adrenergic agonists [ 21 , 22 ], alpha-adrenergic agonists [ 23 ], beta-blockers [ 24 , 25 ], carbonic anhydrase inhibitors [ 26 ], prostaglandin analogs [ 27 - 29 ], and Rho-associated coiled-coil protein kinase (ROCK) inhibitors [ 30 ], have been developed and used to treat glaucoma. These molecular agents can lower IOP by reducing the rate of AH formation, increasing the outflow of AH from the unconventional outflow pathway, or decreasing the outflow resistance of AH in the conventional outflow pathway [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma

Wu,

Wei,

Chen

et al. 2024

CDT

View full text Add to dashboard Cite

Glaucoma is the most common cause of irreversible blindness worldwide. It is characterized by progressive optic nerve degeneration and loss of visual field. Pathological increased intraocular pressure is its main modifiable risk factor. Rho kinase inhibitors are developed as a new class of glaucoma medication that increases outflow facility from the conventional aqueous humor outflow pathway. Additionally, they also have neuropective and anti-scarring effects that can might increase the success rate of glaucoma filtration surgery. This review aims to summarize the current concept of Rho kinase inhibitor in the treatment of glaucoma from beach to bedside.

show abstract

Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research

Cited by 15 publications

References 92 publications

miRNA Studies in Glaucoma: A Comprehensive Review of Current Knowledge and Future Perspectives

miRNA Studies in Glaucoma: A Comprehensive Review of Current Knowledge and Future Perspectives

When to treat ocular hypertension?

Rho Kinase (ROCK) Inhibitors for the Treatment of Glaucoma

Contact Info

Product

Resources

About